RxDoctor Payments DataLook up a doctor →

Kirk Harum, MD

Pain Medicine · New Bern, NCNPI 1013904614

Payments from drug & device makers

$50,349in general payments, 2019–2025

Across 684 payments — averaging $73.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$31K
  • Saluda Medical Americas, Inc.$5K
  • Medtronic$3K
  • Relievant Medsystems, Inc.$2K
  • Nevro Corp.$2K
  • Spinal Simplicity, LLC$2K
  • plus $5K from 49 others

What the payments were for

  • Travel & lodging$6,57729%
  • Food & beverage$16,47571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,349 in reported general payments places this provider in the 90th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$388,196
Medicare patients
475
Services billed
13,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate14$12,670
QuliptaAtogepant12$12,107
Buprenorphine35$11,398
OxycontinOxycodone Hcl12$9,463
Oxycodone Hcl250$5,649
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen172$5,377
Morphine Sulfate ErMorphine Sulfate63$2,639
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen118$2,551
Gabapentin200$2,414
Pregabalin43$2,118
Lidocaine21$1,100
Tramadol Hcl94$894
ProgesteroneProgesterone, Micronized13$820
Tizanidine Hcl46$715
Cyclobenzaprine Hcl48$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$341$12,67014 claims
AbbVieQulipta$567$12,10712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →